Merck&Co reports EPS of $1.03 in Q2, up 63% YoY

Dienstag, 30. Juli 2019 12:48

American pharmaceutical giant Merck & Co. Inc. reported on Tuesday its GAAP earnings per share for the second quarter of 2019 stood at $1.03, increasing 63% on an annual basis. The company's worldwide sales amounted to $11.8 billion, up 12% compared to the same time period last year and its net income reached a figure of $2.7 billion, marking an 56% increase year over year.

Growth was driven by Oncology and Human Health Vaccines, with KEYTRUDA and Human Health Vaccines sales sales growing 58% and 33% respectively. The company raised its full-year revenue forecast to between $45.2 billion and $46.2 billion. The full-year GAAP EPS were expected to fall between $3.78 and $3.88.

"Our science-led strategy and execution across our key growth pillars have driven another quarter of accelerating revenue growth with strength across our global portfolio. We remain confident that our innovative products and significant pipeline opportunities will continue to deliver strong results and provide sustainable value to patients and shareholders," chief executive officer Kenneth Frazier said in the press release.

Company's shares were up 4.85% premarket after beating market expectations.

Related Links: Merck & Co. Inc.
Breaking the News / MD